CN103002904B - 抗血管生成药剂及使用这种药剂的方法 - Google Patents

抗血管生成药剂及使用这种药剂的方法 Download PDF

Info

Publication number
CN103002904B
CN103002904B CN201180034591.9A CN201180034591A CN103002904B CN 103002904 B CN103002904 B CN 103002904B CN 201180034591 A CN201180034591 A CN 201180034591A CN 103002904 B CN103002904 B CN 103002904B
Authority
CN
China
Prior art keywords
polypeptide
sequence
mice
mankind
angiogenesis inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180034591.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN103002904A (zh
Inventor
刘志仁
詹妮·J·杨
鲁荫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgia State University Research Foundation Inc
Original Assignee
Georgia State University Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgia State University Research Foundation Inc filed Critical Georgia State University Research Foundation Inc
Publication of CN103002904A publication Critical patent/CN103002904A/zh
Application granted granted Critical
Publication of CN103002904B publication Critical patent/CN103002904B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN201180034591.9A 2010-07-13 2011-07-13 抗血管生成药剂及使用这种药剂的方法 Active CN103002904B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36393310P 2010-07-13 2010-07-13
US61/363,933 2010-07-13
PCT/US2011/043907 WO2012009471A1 (en) 2010-07-13 2011-07-13 Anti-angiogenic agent and method of using such agent

Publications (2)

Publication Number Publication Date
CN103002904A CN103002904A (zh) 2013-03-27
CN103002904B true CN103002904B (zh) 2017-01-18

Family

ID=44629339

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180034591.9A Active CN103002904B (zh) 2010-07-13 2011-07-13 抗血管生成药剂及使用这种药剂的方法

Country Status (12)

Country Link
US (2) US9175063B2 (es)
EP (2) EP2593127B1 (es)
JP (2) JP6353654B2 (es)
CN (1) CN103002904B (es)
AU (5) AU2011279155B2 (es)
CA (1) CA2804753C (es)
DK (1) DK2593127T3 (es)
ES (2) ES2674409T3 (es)
HU (1) HUE040205T2 (es)
PL (1) PL2593127T3 (es)
PT (2) PT2593127T (es)
WO (1) WO2012009471A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6353654B2 (ja) * 2010-07-13 2018-07-04 ジョージア・ステイト・ユニヴァーシティ・リサーチ・ファウンデイション 抗血管新生剤及びこのような薬剤の使用方法
WO2016144815A1 (en) * 2015-03-06 2016-09-15 Georgia State University Research Foundation, Inc. Integrin-targeting protein and methods of use thereof
CN106674352B (zh) * 2015-11-10 2020-05-15 孙嘉琳 抗肿瘤蛋白内皮抑素的衍生物及应用
CN108148117A (zh) * 2017-12-26 2018-06-12 张艳雪 一种抗菌肽的蛋白质结构特性及其研究方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008187A1 (en) * 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
CN1953766A (zh) * 2004-02-06 2007-04-25 安斯泰来美国有限公司 治疗皮肤病的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
AU2003273299B2 (en) * 2002-09-05 2010-04-01 Medimmune, Llc Methods of preventing or treating cell malignancies by administering CD2 antagonists
US9339559B2 (en) * 2005-09-09 2016-05-17 Georgia State University Research Foundation, Inc. Targeted contrast agents and methods for targeting contrast agents
EP2257316B1 (en) * 2008-04-02 2018-11-07 Georgia State University Research Foundation, Inc. Contrast agents, methods for preparing contrast agents, and methods of imaging
EP2599497A3 (en) * 2008-09-08 2013-09-25 Hoffman/Barrett, L.L.C. Porphyrazine-chemotherapeutic agents conjugates
JP6353654B2 (ja) * 2010-07-13 2018-07-04 ジョージア・ステイト・ユニヴァーシティ・リサーチ・ファウンデイション 抗血管新生剤及びこのような薬剤の使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008187A1 (en) * 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
CN1953766A (zh) * 2004-02-06 2007-04-25 安斯泰来美国有限公司 治疗皮肤病的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
N-glycosylation is required for human CD2 immunoadhesion function;RECNY;《Journal of biological chemistry》;19920101;第267卷(第31期);第22428页 *

Also Published As

Publication number Publication date
AU2019202174A1 (en) 2019-04-18
AU2021201207A1 (en) 2021-03-11
US11578114B2 (en) 2023-02-14
CA2804753C (en) 2021-05-25
WO2012009471A1 (en) 2012-01-19
AU2017201133A1 (en) 2017-03-09
AU2019202174B2 (en) 2020-11-26
JP6353654B2 (ja) 2018-07-04
EP3381462A1 (en) 2018-10-03
JP2016175913A (ja) 2016-10-06
US20130281357A1 (en) 2013-10-24
CN103002904A (zh) 2013-03-27
EP3381462B1 (en) 2022-06-08
JP2013534538A (ja) 2013-09-05
DK2593127T3 (en) 2018-07-02
PL2593127T3 (pl) 2018-11-30
AU2023202513A1 (en) 2023-05-11
US9175063B2 (en) 2015-11-03
AU2011279155A1 (en) 2013-01-24
ES2674409T3 (es) 2018-06-29
AU2011279155B2 (en) 2017-03-09
EP2593127B1 (en) 2018-05-30
ES2923430T3 (es) 2022-09-27
EP2593127A1 (en) 2013-05-22
PT2593127T (pt) 2018-07-06
HUE040205T2 (hu) 2019-02-28
US20160090408A1 (en) 2016-03-31
PT3381462T (pt) 2022-07-22
CA2804753A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
AU2019202174B2 (en) Anti-angiogenic agent and method of using such agent
CN109069470A (zh) 特定苯并二氢呋喃类木脂素于抑制乳癌细胞转移之用途
CA3183703A1 (en) Cancer stem cell targeted cancer vaccines
US20210008173A1 (en) Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury
EP3813870A1 (en) Ccr5 inhibitor for use in treating cancer
TW201642857A (zh) 以組合療法治療肝細胞癌
US20240034766A1 (en) Anti-angiogenic agent and methods of using such agent
WO2024173546A2 (en) Anti-angiogenic agent and methods of using such agent
US20230241167A1 (en) Use of Caveolin-1 Scaffolding Domain Peptides for Treating Disease and Disorders
KR20090061358A (ko) 아카세틴을 유효성분으로 하는 유방암 예방 및 치료용조성물
CA3230917A1 (en) Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury
WO2023173074A2 (en) Immunostimulant-cytotoxic conjugate composition and methods for cancer treatment
WO2007143096A2 (en) Compounds for treating cancers
KR20090061356A (ko) 제니스테인을 포함하는 유방암 치료 및 예방용 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant